{
  "Cluster": "3",
  "CandidateSubtype": "mixed",
  "TopGenes": [
    "TOP2A",
    "MKI67",
    "APOB",
    "AFP",
    "ITIH2",
    "SERPINA1",
    "RNA28S5",
    "AHSG",
    "CENPF",
    "IGF2",
    "SPINK1",
    "APOM",
    "PEG10",
    "ACADSB",
    "GPC3",
    "TF",
    "AHCY",
    "DLK1",
    "ACSL4",
    "APOA2"
  ],
  "ProliferationScore": "0.641 (intermediate)",
  "StemnessScore": "0.195 (low)",
  "ImmuneScore": "0.213 (low)",
  "PrognosticScore": "0.992 (high)",
  "SupportingEvidence": [
    "Co-expression of embryonal/progenitor markers: DLK1, IGF2, PEG10, GPC3, AFP",
    "Concurrent high expression of fetal hepatocyte/metabolic genes: APOB, APOA2, SERPINA1, TF, AHSG, APOM",
    "Strong cell-cycle markers (TOP2A, MKI67, CENPF) indicating a proliferative compartment",
    "IGF2 and DLK1 upregulation consistent with 11p15 dysregulation commonly seen in hepatoblastoma",
    "AFP and GPC3 overexpression characteristic of hepatoblastoma, including embryonal areas"
  ],
  "SuggestedExperiments": [
    "Immunohistochemistry: GPC3, DLK1, AFP, Ki-67; add HepPar-1/ALB to gauge hepatocytic differentiation",
    "Assess Wnt/\u03b2-catenin activation: CTNNB1 sequencing and nuclear \u03b2-catenin IHC; AXIN2 expression",
    "11p15 (IGF2/H19) methylation and loss-of-imprinting analysis",
    "Spatial transcriptomics or multiplex RNA-ISH to map co-localization of embryonal and fetal markers",
    "Single-cell cell-cycle phase assignment and RNA velocity to confirm proliferative dynamics"
  ]
}